Results
preeclampsia
PREECLAMPSIA
Of all 2348 participants (mean [SD] age, 25.1 [5.4] years; 952 Black participants [40.5%]; 502 Hispanic participants [21.4%]; 863 White participants [36.8%]), 1176 participants were randomized to the GPNC group and 1174 were randomized to the IPNC group. Among all participants, 2144 (91.3%) completed a GD screening (1072 participants [91.3%] in GPNC vs 1071 [91.2%] in IPNC). Overall, 157 participants (6.7%) developed GD, and there was no difference in GD incidence between the GPNC (83 participants [7.1%]) and IPNC (74 participants [6.3%]) groups, with an adjusted RD of 0.7% (95% CI, −1.2% to 2.7%). Among participants with GD, GPNC did not reduce the risk of progression to A2 GD (adjusted RD, −6.1%; 95% CI, −21.3% to 9.1%), preeclampsia (adjusted RD, −7.9%; 95% CI, −17.8% to 1.9%), cesarean delivery (adjusted RD, −8.2%; 95% CI, −12.2% to 13.9%), and large for gestational age (adjusted RD, −1.2%; 95% CI, −6.1% to 3.8%) compared with IPNC.